3,4,3-LI(1,2-HOPO) has been identified as an excellent alternative for DTPA for decorporating actinides, such as Pu and Am, after internal contamination. Efforts have been focused on its application through oral administration. When 3,4,3-LI(1,2-HOPO) was encapsulated with biocompatible, biodegradable nanoparticles made of chitosan, its release from the nanoparticles to lung fluid, observed in in vitro experiments, exhibited an extended release profile. These observations were very encouraging, as this nanomedicine could lead to a reduction in the dosing frequency required to achieve the decorporation efficacy of unformulated 3,4,3-LI(1,2-HOPO) itself. In vivo release tests as well as actinide decorporation experiments, using an inhalation exposure animal model, will follow.

Additional Metadata
Persistent URL dx.doi.org/10.1093/rpd/ncy139
Journal Radiation protection dosimetry
Citation
Chen, S. (Sijing), Ko, R. (Raymond), Lai, E. P, Wyatt, H. (Heather), Abergel, R.J. (Rebecca J.), & Li, C. (Chunsheng). (2018). ENCAPSULATED 3,4,3-LI(1,2-HOPO) IN CHITOSAN NANOPARTICLES FOR DECORPORATION VIA INHALATION. Radiation protection dosimetry, 182(1), 107–111. doi:10.1093/rpd/ncy139